Evidence map›Paper›PMID 23314907›Full record

ReviewCurrent opinion in HIV and AIDS2013

New assays for monitoring residual HIV burden in effectively treated individuals.

Matthew C Strain, Douglas D Richman

Open access · greenAbstract readReview
In one paragraph

Review in Current opinion in HIV and AIDS, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Diagnostic Molecular Microbiology: A 2018 Snapshot.Clinics in laboratory medicine · 2018
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Finding a cure for human immunodeficiency virus-1 infection.Infectious disease clinics of North America · 2014
    Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Matthew C StrainUniversity of California San Diego, La Jolla, California 92093-0679, USA.
Douglas D Richman
VA San Diego Healthcare System · US

Funding

VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI David Mitchell Smith · 1994 to 2026
$78.4M
UCSD Department of Medicine HIV/AIDS Clinical Trials UnitUM1AI069432 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TIMOTHY J. WILKIN · 2012 to 2026
$50.4M
Using NK Cells to eliminate the latent HIV reservoirU19AI096113 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI WOELK, CHRISTOPHER H · 2011 to 2015
$39.5M
Transmission ProbabilityP01AI074621 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI RICHMAN, DOUGLAS D · 2008 to 2012
$23.1M
Primary Infection Resource Consortium (PIRC)R24AI106039 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LITTLE, SUSAN JANET · 2013 to 2021
$23.1M
UCSD Department of Medicine HIV/AIDS Clinical Trials UnitU01AI069432 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BENSON, CONSTANCE ANN · 2007 to 2011
$19.3M
Biomathematical analysis of viral dynamics/evolutionR01AI047745 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI RICHMAN, DOUGLAS D · 2001 to 2011
$3.2M
Targeting regulators of cellular gene transcription to impact HIV latencyP01AI080193 · NIAID · VETERANS MEDICAL RESEARCH FDN/SAN DIEGO · PI RICHMAN, DOUGLAS D · 2009 to 2010
$1.8M
Biomathematical Analysis of Viral Dynamics and EvolutionR56AI047745 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI POND, SERGEI L KOSAKOVSKY · 2012 to 2012
$365k
BIOMATHEMATICAL ANALYSIS OF VIRAL DYNAMICS AND EVOLUTIONR21AI047745 · NIAID · UNIVERSITY OF CALIFORNIA SAN DIEGO · PI RICHMAN, DOUGLAS D · 2000 to 2000
$308k
NIAID NIH HHS AI047745NIAID NIH HHS AI080193NIAID NIH HHS AI096113NIAID NIH HHS AI306214NIAID NIH HHS AI69432NIAID NIH HHS AI74621NIAID NIH HHS P01 AI074621NIAID NIH HHS P01 AI080193NIAID NIH HHS P30 AI036214NIAID NIH HHS R01 AI047745NIAID NIH HHS R21 AI047745NIAID NIH HHS R24 AI106039NIAID NIH HHS R56 AI047745NIAID NIH HHS U01 AI069432NIAID NIH HHS U19 AI096113NIAID NIH HHS UM1 AI069432
6 · The paper itself

Abstract

purpose of reviewMeasurements of HIV burden have relied upon quantification of viral nucleic acids by real-time PCR (qPCR). To develop and test strategies for eradication, new methods are needed to better characterize residual cellular reservoirs in patients on suppressive antiretroviral therapy (ART). This review summarizes recent advances that may lead to clinically useful tests with improved sensitivity, reproducibility and throughput. RECENT

findingsHIV DNA remains the most sensitive measure of residual infection, but its low levels are difficult to differentiate from assay noise by qPCR. Digital PCR has begun to improve the precision of existing real-time assays, but there remains a need to distinguish replication-competent proviruses. Rapid technological progress in single-cell analysis is beginning to offer new approaches, notably CyTOF and microengraving, which could provide vastly more information about the composition of the latent reservoir. SUMMARY: To investigate and assess therapies directed towards eradication, improved assays that simultaneously offer high sensitivity, precision and information content will be needed.

Indexed as

Anti-HIV AgentsDNA, ViralDrug MonitoringHIVHIV InfectionsHumansProvirusesViral LoadAnti-HIV AgentsDNA, Viral

Identifiers

PMID23314907
PMCPMC3754420
OpenAlexW2069478317

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.